Dr. Ferreira received his PhD training in the area of neuroimmunology, with a particular focus on the physiological mechanisms by which brain inflammation can be curbed, which is especially relevant to the neural harm that can occur with neurodegenerative disease, traumatic injury, and stroke. Roger has authored several peer-reviewed publications in the Journal of Neuroimmune Pharmacology, Frontiers in Cellular Neuroscience, Frontiers in Cellular Immunology, and the Public Library of Science; as well as having presented his work at several international conferences, including the Biophysical Society 56th Annual Meeting (San Diego, California, USA, 2012), the 7th Annual Canadian Neuroscience meeting (Toronto, Ontario, Canada, 2013), and the Biophysical Society 59th Annual Meeting (Baltimore, Maryland, USA, 2015). His area of research is particularly relevant to medical marihuana, as there is strong pre-clinical evidence that cannabidiol, the non-psychoactive ingredient, can limit the ability of brain immune cells to cause excessive inflammation, an exciting area of research that will reveal how particular strains of medical marihuana have the potential to not only alleviate symptoms of disease, but also reduce brain inflammation and disease progression. In addition, Dr. Ferreira brings his extensive training in microbiology and analytical chemistry to FAM’s quality assurance process. He will be responsible for overseeing all marihuana quality assurance testing provisioned under the MMPR, and applies his substantial training in laboratory management at the University of Toronto, and Toronto Western Research Institute (University Health Network) to oversee all good production practice